Results 41 to 50 of about 12,272 (191)

PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis

BMC Musculoskeletal Disorders
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent an effective strategy for reducing cardiovascular disease risk. Yet, PCSK9’s impact on osteoporosis remains unclear.
Ding-Qiang Chen, Wen-Bin Xu, Ke-Yi Xiao, Zhi-Qiang Que, Jin-Yi Feng, Nai-Kun Sun, Di-Xin Cai, Gang Rui   +7 more
doaj   +1 more source

The Evolving Future of PCSK9 Inhibitors

Journal of the American College of Cardiology, 2018
Variants in proprotein convertase subtilisin/kexin type 9 (PCSK9) provide insights into mechanisms regulating low-density lipoprotein (LDL) levels. Human monoclonal antibodies that target PCSK9 lower LDL cholesterol (LDL-C) levels by 55% to 72% in different high-risk patient groups.
Robert S, Rosenson, Robert A, Hegele, Sergio, Fazio, Christopher P, Cannon   +3 more
openaire   +2 more sources

Engineering Antibodies into Targeted Chimeras: From Recognition Modules to Programmable Degraders

Advanced Science, EarlyView.
Antibody can be engineered into diverse lysosome‐targeting chimeras that convert target recognition into active degradation. By coupling antibody binding with recruited receptors, encoded domains, conjugated ligands, or nanoparticle scaffolds, these antibody‐associated targeted chimeras (AbTACs) platforms direct extracellular and membrane proteins ...
Kaige Chen, Quanyin Hu
wiley   +1 more source

Dual‐Organelle Secretome Conjugation and Organ‐Uptake Tracking (DuO‐SCOUT) Enables Deep and Sensitive Mapping of the Secreted Proteins

Advanced Science, EarlyView.
A novel dual‐organelle proximity labeling platform, DuO‐SCOUT, decodes the complex landscape of systemic organ‐organ communication by capturing both classical and unconventional secretomes. Application in metabolic models maps the adipose‐to‐brain secretory relay, identifying selective extra‐hypothalamic sites for adipose‐derived factors and expanding ...
Fenglian Yang, Rui Qian, Jiaxing Song, Xingqi Meng, Jin Young Kim, Kwok On Lai, Li Wang, Liang Zhang   +7 more
wiley   +1 more source

Causal relationship between lipid-lowering drugs and ovarian cancer, cervical cancer: a drug target mendelian randomization study

BMC Cancer
Background The causal impact of lipid-lowering drugs on ovarian cancer (OC) and cervical cancer (CC) has received considerable attention, but its causal relationship is still a subject of debate.
Jinshuai Li, Zixian Yang, Tao Wang, Mengqi Li, Xiangjian Wu, Xiaoyan Fu, Chunfeng Yang, Yangpu Li, Ximing Wang, Zhiming Lan, Minfang Li, Sheng Chen   +11 more
doaj   +1 more source

Natural phytochemicals as small-molecule proprotein convertase subtilisin/kexin type 9 inhibitors

Tzu Chi Medical Journal
A decrease in the levels of low-density lipoprotein receptors (LDLRs) leads to the accumulation of LDL cholesterol (LDL-C) in the bloodstream, resulting in hypercholesterolemia and atherosclerotic cardiovascular diseases.
Je-Wen Liou, Pei-Yi Chen, Wan-Yun Gao, Jui-Hung Yen   +3 more
doaj   +1 more source

Assessing the safety of lipid-modifying medications among Chinese adolescents: a drug-target Mendelian randomization study

BMC Medicine, 2023
Background With increasing hypercholesterolemia prevalence in East Asian adolescents, pharmacologic interventions (e.g., HMGCR inhibitors (statins) and PCSK9 inhibitors) may have to be considered although their longer-term safety in the general ...
Shan Luo, Hugh Simon Lam, Yap Hang Chan, Clara Sze Man Tang, Baoting He, Man Ki Kwok, Gabriel M. Leung, C Mary Schooling, Shiu Lun Au Yeung   +8 more
doaj   +1 more source

The efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors combined with statins in patients with hypercholesterolemia: a network meta-analysis

Frontiers in Cardiovascular Medicine
BackgroundIn recent years, the position of PCSK9 inhibitors as adjuvant therapy to statins in guidelines has further improved. However, there remained a dearth of direct comparative studies among different PCSK9 inhibitors. Therefore, this study aimed to
Dong Liu, Jin Zhang, Xiaoyu Zhang, Fengli Jiang, Yiping Wu, Beibei Yang, Xinghuan Li, Xiongxiong Fan, Han Li, Yu Sun, Ruijie Gou, Xinyu Wang   +11 more
doaj   +1 more source

A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro

Molecules, 2018
The interaction between proprotein convertase subtilisin/kexin type 9 (PCSK9) and the low-density lipoprotein receptor (LDLR) is a promising target for the treatment of hyperc-holesterolemia.
Li Li, Chen Shen, Ya-Xuan Huang, Ya-Nan Li, Xiu-Feng Liu, Xu-Ming Liu, Ji-Hua Liu   +6 more
doaj   +1 more source

Neurocognitive effects associated with proprotein convertase subtilisin-kexin type 9 inhibitor use: a narrative review

Therapeutic Advances in Drug Safety, 2021
Neurocognitive adverse events have been observed with the widespread use of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors or “statins,” which reduce low-density lipoprotein cholesterol (LDL-C) levels and subsequently cardiovascular risk. The United
Wei C. Yuet, Didi Ebert, Michael Jann
doaj   +1 more source